Sandoz analysis sees $94 billion in potential Canadian drug savings through 2035

By Public Technologies
  • Sandoz Canada's Oct. 28, 2026 analysis estimates $94 billion in potential Canadian generic and biosimilar savings over 2026-2035.
  • More than 300 medicines will lose exclusivity or are already open to competition without market entry, representing $24 billion in annual branded-medicine value.
  • Opportunities include more than 250 generic medicines valued at $13 billion annually and more than 80 biological medicines valued at $11 billion.
  • Without timely market entry, payers could face $183 billion in cumulative spending on higher-cost branded treatments.
  • Realizing savings requires predictable regulatory processes, fewer market-entry barriers and policies supporting timely adoption of lower-cost alternatives.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novartis AG published the original content used to generate this news brief via CNW (Ref. ID: 202610280700CANADANWCANADAPR_C8002) on October 28, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk